---
title: "Savara | 10-K: FY2025 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279041305.md"
datetime: "2026-03-13T12:14:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279041305.md)
  - [en](https://longbridge.com/en/news/279041305.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279041305.md)
---

# Savara | 10-K: FY2025 Revenue: USD 0

Revenue: As of FY2025, the actual value is USD 0.

EPS: As of FY2025, the actual value is USD -0.53, missing the estimate of USD -0.5163.

EBIT: As of FY2025, the actual value is USD -127.71 M.

Savara Inc. operates in a single segment, focusing on specialty pharmaceuticals within the respiratory system, and therefore does not report segmented financial metrics .

#### Operational Metrics (YoY Comparison)

-   **Net Loss:** Savara Inc. reported a net loss of -$118.8 million for the year ended December 31, 2025, an increase from -$95.9 million for the year ended December 31, 2024 .
-   **Research and Development Expenses:** These expenses increased by $3.4 million, or 4.3%, to $81.4 million for the year ended December 31, 2025, compared to $78.0 million for the year ended December 31, 2024 . This increase was primarily due to $5.7 million in regulatory affairs and quality assurance costs, $0.5 million in chemistry, manufacturing, and controls activities, and $1.0 million in other departmental overhead, partially offset by a -$3.8 million decrease in clinical costs .
-   **General and Administrative Expenses:** These expenses increased by $17.0 million, or 68.0%, to $42.1 million for the year ended December 31, 2025, from $25.0 million for the year ended December 31, 2024 . This rise was driven by $11.2 million in higher personnel and related costs, $3.1 million for certain commercial activities, and $2.7 million in other overhead .
-   **Depreciation and Amortization:** This decreased to $87 thousand for the year ended December 31, 2025, from $130 thousand in 2024 .
-   **Total Operating Expenses:** Total operating expenses were $123.5 million in 2025, up from $103.2 million in 2024 .
-   **Other Income, Net:** Other income, net decreased by -$2.6 million to $4.7 million for the year ended December 31, 2025, from $7.3 million for the year ended December 31, 2024, primarily due to lower interest income and a -$546 thousand loss on extinguishment of debt .
    -   **Interest Income, Net:** $4.2 million in 2025 compared to $6.5 million in 2024 .
    -   **Foreign Currency Exchange Gain:** $310 thousand in 2025 compared to $51 thousand in 2024 .
    -   **Tax Credit Income:** $784 thousand in 2025 compared to $797 thousand in 2024 .
    -   **Loss on Extinguishment of Debt:** -$546 thousand in 2025 compared to $0 in 2024 .

#### Cash Flow

-   **Cash Used in Operating Activities:** -$101.0 million for the year ended December 31, 2025, compared to -$89.1 million for the year ended December 31, 2024 .
-   **Cash Used in Investing Activities:** -$18.4 million for the year ended December 31, 2025, compared to -$39.9 million for the year ended December 31, 2024 .
-   **Cash Provided by Financing Activities:** $137.8 million for the year ended December 31, 2025, compared to $117.6 million for the year ended December 31, 2024 .

#### Balance Sheet Metrics (as of December 31, 2025)

-   **Cash and Cash Equivalents:** $33.2 million .
-   **Short-term Investments:** $202.5 million .
-   **Accumulated Deficit:** -$608.1 million .
-   **Working Capital:** $221.2 million .
-   **Long-term Debt:** $29.9 million .

#### Outlook / Guidance

Savara Inc. anticipates substantial operating losses in the foreseeable future due to the clinical development, regulatory approvals, and commercialization of its MOLBREEVI product candidate . Research and development expenses are expected to remain significant, driven by increased investment in regulatory support and contract manufacturing . The company plans to meet future funding requirements through existing capital, equity offerings, debt financings, and strategic alliances .

### Related Stocks

- [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md)

## Related News & Research

- [A Look At Savara (SVRA) Valuation After Strong 1 Year Shareholder Return](https://longbridge.com/en/news/282944525.md)
- [Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference | SVRA Stock News](https://longbridge.com/en/news/282687737.md)
- [Northland Securities Estimates RELL FY2026 Earnings](https://longbridge.com/en/news/282488579.md)
- [D’Ieteren SA (0ON7) Initiated with a Buy at Bernstein](https://longbridge.com/en/news/283038857.md)
- [Salesforce Inc. $CRM Shares Sold by Lbp Am Sa](https://longbridge.com/en/news/282981299.md)